Tenofovir alafenamide hemifumarate

Tenofovir alafenamide hemifumarate (CAS No.: 1392275-56-7) is a small molecule nucleotide analog prodrug and antiviral research compound, commonly classified within phosphonamidate prodrug systems and used in biomedical investigations as a precursor form of tenofovir for mechanistic studies of viral replication control, where its functional background is defined by intracellular bioconversion pathways that increase cellular delivery of the active tenofovir related metabolite pool relative to extracellular exposure, thereby supporting experimental interrogation of HIV 1 reverse transcriptase associated nucleotide incorporation processes and nucleic acid synthesis blockade in relevant model systems; in research settings, its primary target category is viral reverse transcriptase through the tenofovir active metabolite generated after cellular activation, and the principal mechanism is understood as nucleotide analog mediated inhibition of reverse transcription with downstream suppression of viral genome replication, with reported in vitro antiviral potency for this class generally observed from nanomolar to low micromolar ranges depending on cell type, viral strain, activation state, and assay format, while broader applications include cell based antiviral profiling, resistance and combination screening paradigms, pharmacology oriented exposure response characterization, and translational preclinical studies in animal models of viral infection biology, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.